Regulation of in vivo behavior of TAT-modified liposome by associated protein corona and avidity to tumor cells

References

• GregoriadisGLiposomology: delivering the messageJ Liposome Res20182811429382287
   PubMed Web of Science ®Google Scholar
• VendittoVJSzokaFCJrCancer nanomedicines: so many papers and so few drugs!Adv Drug Deliv Rev2013651808823036224
   PubMed Web of Science ®Google Scholar
• BiswasSDeshpandePPPercheFDodwadkarNSSaneSDTorchilinVPOcta-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancerCancer Lett2013335119120023419527
   PubMed Web of Science ®Google Scholar
• BarenholzYDoxil® – the first FDA-approved nano-drug: lessons learnedJ Control Release2012160211713422484195
   PubMed Web of Science ®Google Scholar
• BulbakeUDoppalapudiSKommineniNKhanWLiposomal formulations in clinical use: an updated reviewPharmaceutics20179212
   PubMed Web of Science ®Google Scholar
• MaedaHMacromolecular therapeutics in cancer treatment: the EPR effect and beyondJ Control Release2012164213814422595146
   PubMed Web of Science ®Google Scholar
• AllenTMCullisPRLiposomal drug delivery systems: from concept to clinical applicationsAdv Drug Deliv Rev2013651364823036225
   PubMed Web of Science ®Google Scholar
• GabizonAShmeedaHHorowitzATZalipskySTumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugatesAdv Drug Deliv Rev20045681177119215094214
   PubMed Web of Science ®Google Scholar
• van der MeelRVehmeijerLJCKokRJStormGvan GaalEVBLigand-targeted particulate nanomedicines undergoing clinical evaluation: current statusAdv Drug Deliv Rev201365101284129824018362
   PubMed Web of Science ®Google Scholar
• CaraccioloGLiposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicinesNanomedicine201511354355725555353
   PubMed Web of Science ®Google Scholar
• AnchordoquyTJBarenholzYBoraschiDMechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutionsACS Nano2017111121828068099
   PubMed Web of Science ®Google Scholar
• LammersTKiesslingFAshfordMHenninkWCrommelinDStormGCancer nanomedicine: Is targeting our target?Nat Rev Mater2016191606927668091
   PubMed Web of Science ®Google Scholar
• AminMBadieeAJaafariMRImprovement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomasInt J Pharm2013458232433324148663
   PubMedGoogle Scholar
• WangFWangYZhangXZhangWGuoSJinFRecent progress of cell-penetrating peptides as new carriers for intracellular cargo deliveryJ Control Release201417412613624291335
   PubMed Web of Science ®Google Scholar
• SarkoDBeijerBGarcia BoyRThe pharmacokinetics of cell-penetrating peptidesMol Pharm2010762224223120845937
   PubMedGoogle Scholar
• BecharaCSaganSCell-penetrating peptides: 20 years later, where do we stand?FEBS Lett2013587121693170223669356
   PubMed Web of Science ®Google Scholar
• BrooksHLebleuBVivèsETat peptide-mediated cellular delivery: back to basicsAdv Drug Deliv Rev200557455957715722164
   PubMed Web of Science ®Google Scholar
• TsengYLLiuJJHongRLTranslocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy studyMol Pharmacol200262486487212237333
   PubMed Web of Science ®Google Scholar
• RizzutiMNizzardoMZanettaCRamirezACortiSTherapeutic applications of the cell-penetrating HIV-1 Tat peptideDrug Discov Today2015201768525277319
   PubMed Web of Science ®Google Scholar
• PaeJSäälikPLiivamägiLTranslocation of cell-penetrating peptides across the plasma membrane is controlled by cholesterol and microenvironment created by membranous proteinsJ Control Release201419210311325016968
   PubMed Web of Science ®Google Scholar
• AmandHLBoströmCLLincolnPNordénBEsbjörnerEKBinding of cell-penetrating penetratin peptides to plasma membrane vesicles correlates directly with cellular uptakeBiochim Biophys Acta2011180871860186721447320
   PubMed Web of Science ®Google Scholar
• KorenEApteAJaniATorchilinVPMultifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicityJ Control Release2012160226427322182771
   PubMed Web of Science ®Google Scholar
• TorchilinVPRammohanRWeissigVLevchenkoTSTAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitorsProc Natl Acad Sci U S A200198158786879111438707
   PubMed Web of Science ®Google Scholar
• ChungSKMaitiKKLeeWSRecent advances in cell-penetrating, non-peptide molecular carriersInt J Pharm20083541–2162217890027
   PubMedGoogle Scholar
• FretzMMKoningGAMastrobattistaEJiskootWStormGOVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosisBiochim Biophys Acta200416651–2485615471570
   PubMed Web of Science ®Google Scholar
• GumpJMDowdySFTAT transduction: the molecular mechanism and therapeutic prospectsTrends Mol Med2007131044344817913584
   PubMed Web of Science ®Google Scholar
• GuptaBLevchenkoTSTorchilinVPIntracellular delivery of large molecules and small particles by cell-penetrating proteins and peptidesAdv Drug Deliv Rev200557463765115722168
   PubMed Web of Science ®Google Scholar
• TorchilinVPTat peptide-mediated intracellular delivery of pharmaceutical nanocarriersAdv Drug Deliv Rev2008604–554855818053612
   PubMed Web of Science ®Google Scholar
• BartlettGRPhosphorus assay in column chromatographyJ Biol Chem1959234346646813641241
   PubMed Web of Science ®Google Scholar
• SeynhaeveALHovingSSchipperDTumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor responseCancer Res200767199455946217909055
   PubMed Web of Science ®Google Scholar
• LiLTen HagenTLHossannMMild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacyJ Control Release2013168214215023524188
   PubMed Web of Science ®Google Scholar
• AminMMansourianMKoningGABadieeAJaafariMRTen HagenTLMDevelopment of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor regionJ Control Release2015220Pt A30831526526970
   PubMedGoogle Scholar
• HuangZSzokaFCSterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane propertiesJ Am Chem Soc200813046157021571218950160
   PubMed Web of Science ®Google Scholar
• HuangZJaafariMRSzokaFCDisterolphospholipids: nonexchangeable lipids and their application to liposomal drug deliveryAngew Chem Int Ed Engl200948234146414919425026
   PubMed Web of Science ®Google Scholar
• JohnstoneSAMasinDMayerLBallyMBSurface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophagesBiochim Biophys Acta200115131253711427191
   PubMed Web of Science ®Google Scholar
• LasicDDFrederikPMStuartMCBarenholzYMcintoshTJGelation of liposome interior. A novel method for drug encapsulationFEBS Lett19923122–32552581426260
   PubMed Web of Science ®Google Scholar
• WolframJSuriKYangYShrinkage of pegylated and non-pegylated liposomes in serumColloids Surf B Biointerfaces201411429430024216620
   PubMed Web of Science ®Google Scholar
• HadjidemetriouMAl-AhmadyZKostarelosKTime-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticlesNanoscale20168136948695726961355
   PubMed Web of Science ®Google Scholar
• HadjidemetriouMAl-AhmadyZMazzaMCollinsRFDawsonKKostarelosKIn vivo biomolecule corona around blood-circulating, clinically used and antibody-targeted lipid bilayer nanoscale vesiclesACS Nano2015988142815626135229
   PubMed Web of Science ®Google Scholar
• MahonESalvatiABaldelli BombelliFLynchIDawsonKADesigning the nanoparticle-biomolecule interface for “targeting and therapeutic delivery”J Control Release2012161216417422516097
   PubMed Web of Science ®Google Scholar
• MaclarenIAPetrasMLIsolation and properties of serum albumin from the house mouse Mus musculusBiochim Biophys Acta19764271238250816380
   PubMedGoogle Scholar
• PiaoLLiHTengLHuman serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancerNanomedicine20139112212922542825
   PubMed Web of Science ®Google Scholar
• BigdeliAPalchettiSPozziDExploring cellular interactions of liposomes using protein corona fingerprints and physicochemical propertiesACS Nano20161033723373726882007
   PubMed Web of Science ®Google Scholar
• SahaKRahimiMYazdaniMRegulation of macrophage recognition through the interplay of nanoparticle surface functionality and protein coronaACS Nano20161044421443027040442
   PubMed Web of Science ®Google Scholar
• PozziDCaraccioloGDigiacomoLThe biomolecular corona of nanoparticles in circulating biological mediaNanoscale2015733139581396626222625
   PubMed Web of Science ®Google Scholar
• CedervallTLynchIFoyMDetailed identification of plasma proteins adsorbed on copolymer nanoparticlesAngew Chem Int Ed Engl200746305754575617591736
   PubMed Web of Science ®Google Scholar
• LynchISalvatiADawsonKAProtein-nanoparticle interactions: What does the cell see?Nat Nanotechnol20094954654719734922
   PubMed Web of Science ®Google Scholar
• Fogh-AndersenNBjerrumPJSiggaard-AndersenOIonic binding, net charge, and Donnan effect of human serum albumin as a function of pHClin Chem199339148528419057
   PubMed Web of Science ®Google Scholar
• DanhierFFeronOPréatVTo exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug deliveryJ Control Release2010148213514620797419
   PubMed Web of Science ®Google Scholar
• PodhajcerOLBenedettiLGGirottiMRPradaFSalvatierraELleraASThe role of the matricellular protein SPARC in the dynamic interaction between the tumor and the hostCancer Metastasis Rev200827469170518542844
   PubMed Web of Science ®Google Scholar
• TaiITTangMJSPARC in cancer biology: its role in cancer progression and potential for therapyDrug Resist Updat200811623124618849185
   PubMed Web of Science ®Google Scholar
• YardleyDAnab-Paclitaxel mechanisms of action and deliveryJ Control Release2013170336537223770008
   PubMed Web of Science ®Google Scholar
• DesaiNTrieuVDamascelliBSoon-ShiongPSPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patientsTransl Oncol200922596419412420
   PubMed Web of Science ®Google Scholar
• ClarkCJSageEHA prototypic matricellular protein in the tumor microenvironment – where there’s SPARC, there’s fireJ Cell Biochem2008104372173218253934
   PubMed Web of Science ®Google Scholar
• JainRKPhysiological barriers to delivery of monoclonal antibodies and other macromolecules in tumorsCancer Res1990503 Suppl814s819s2404582
   PubMed Web of Science ®Google Scholar
• TangLGabrielsonNPUckunFMFanTMChengJSize-dependent tumor penetration and in vivo efficacy of monodisperse drug-silica nanoconjugatesMol Pharm201310388389223301497
   PubMedGoogle Scholar
• WaiteCLRothCMNanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunitiesCrit Rev Biomed Eng2012401214122428797
   PubMedGoogle Scholar
• HuCMZhangLTherapeutic nanoparticles to combat cancer drug resistanceCurr Drug Metab200910883684120214578
   PubMed Web of Science ®Google Scholar
• AdamsGPSchierRMccallAMHigh affinity restricts the localization and tumor penetration of single-chain fv antibody moleculesCancer Res200161124750475511406547
   PubMed Web of Science ®Google Scholar